Journal of Clinical Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 7, 2025
The
Oncology
Grand
Rounds
series
is
designed
to
place
original
reports
published
in
the
Journal
into
clinical
context.
A
case
presentation
followed
by
a
description
of
diagnostic
and
management
challenges,
review
relevant
literature,
summary
authors'
suggested
approaches.
goal
this
help
readers
better
understand
how
apply
results
key
studies,
including
those
Clinical
Oncology,
patients
seen
their
own
practice.
Journal of Clinical Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 6, 2025
PURPOSE
Datopotamab
deruxtecan
(Dato-DXd)
is
a
trophoblast
cell-surface
antigen-2–directed
antibody-drug
conjugate
with
highly
potent
topoisomerase
I
inhibitor
payload.
The
TROPION-Lung05
phase
II
trial
(ClinicalTrials.gov
identifier:
NCT04484142
)
evaluated
the
safety
and
clinical
activity
of
Dato-DXd
in
patients
advanced/metastatic
non–small
cell
lung
cancer
(NSCLC)
actionable
genomic
alterations
progressing
on
or
after
targeted
therapy
platinum-based
chemotherapy.
PATIENTS
AND
METHODS
Patients
received
6
mg/kg
once
every
3
weeks.
primary
end
point
was
objective
response
rate
(ORR)
by
blinded
independent
central
review.
Secondary
points
included
duration
(DOR),
safety,
tolerability,
survival.
RESULTS
Among
137
who
at
least
1
dose
Dato-DXd,
71.5%
three
lines
prior
therapies
for
disease.
Overall,
56.9%
had
EGFR
mutations
24.8%
ALK
rearrangements.
Median
treatment
4.4
months
(range,
0.7-20.6).
confirmed
ORR
35.8%
(95%
CI,
27.8
to
44.4)
overall,
43.6%
32.4
55.3)
23.5%
10.7
41.2)
those
rearrangements,
respectively.
median
DOR
7.0
4.2
9.8),
overall
disease
control
78.8%
71.0
85.3).
Grade
≥3
treatment-related
adverse
events
(TRAEs)
occurred
28.5%
patients.
most
common
TRAE
stomatitis
(preferred
term;
any
grade:
56.2%;
grade
≥3:
9.5%).
Five
(3.6%)
experienced
adjudicated
interstitial
disease/pneumonitis,
(0.7%)
5
event.
CONCLUSION
Encouraging
durable
antitumor
observed
this
heavily
pretreated
NSCLC
population
alterations.
toxicities
comparable
previous
observations,
no
new
signals
were
observed.
RSC Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Small
molecules
targeting
activating
mutations
within
the
epidermal
growth
factor
receptor
(EGFR)
are
efficacious
anticancer
agents,
particularly
in
non-small
cell
lung
cancer
(NSCLC).
Lung
cancer
remains
the
leading
cause
of
cancer-related
mortality
worldwide.
Since
2024,
non-small-cell
lung
(NSCLC)
landscape
has
undergone
a
transformative
shift,
driven
by
11
FDA
approvals.
Recent
advances
in
molecular
profiling,
targeted
therapies,
and
immunotherapies
have
revolutionized
NSCLC
management,
ushering
an
era
personalized
treatment
with
improved
patient
outcomes.
The
increased
adoption
low-dose
computed
tomography
(LDCT)
for
screening
enhanced
early
detection,
enabling
intervention
at
more
curable
stages.
Molecular
diagnostics
now
play
pivotal
role
guiding
strategies,
actionable
genomic
alterations
(AGAs)
informing
use
EGFR,
ALK,
ROS1,
KRAS,
NRG1,
other
inhibitors
both
advanced
settings.
For
instance,
therapies
are
increasingly
being
integrated
into
early-stage
adjuvant
osimertinib
EGFR-mutated
alectinib
ALK-positive
demonstrating
substantial
survival
benefits.
Immunotherapy,
particularly
immune
checkpoint
inhibitors,
become
cornerstone
AGA-negative
NSCLC,
either
as
monotherapy
or
combination
chemotherapy,
is
utilized
perioperative
setting.
Furthermore,
emerging
such
bispecific
antibodies,
antibody-drug
conjugates
(ADCs),
novel
immunotherapeutic
agents
show
promise
addressing
resistance
mechanisms
improving
outcomes
advanced-stage
disease.
Although
new
challenges
arise,
evolving
paradigm
continues
to
prioritize
precision
medicine,
offering
hope
prolonged
quality
life
patients.
Cancers,
Год журнала:
2024,
Номер
16(5), С. 940 - 940
Опубликована: Фев. 26, 2024
Circulating
tumor
DNA
(ctDNA)
offers
a
new
paradigm
in
optimizing
treatment
strategies
for
epidermal
growth
factor
receptor
(EGFR)
mutant
non-small
cell
lung
cancer
(NSCLC).
Its
potential
spans
early-stage
disease,
influencing
adjuvant
therapy,
to
advanced
where
it
aids
identifying
genomic
markers
and
resistance
mechanisms.
This
review
explores
the
evolving
landscape
of
utilizing
liquid
biopsies,
specifically
circulating
(ctDNA),
management
NSCLC
with
